Skip to content
Peptide research

Endoluten

Also known as Pineal Bioregulator
Category
Bioregulators
Administration routes
Oral
Regulatory status
Not FDA-approved

A bovine pineal-derived bioregulator peptide marketed to restore declining pineal function, melatonin output, and circadian rhythm. Human evidence is thin: melatonin normalization is extrapolated from Epithalamin studies, but neuroendocrine, cardiovascular, and anti-aging claims rest on weak or speculative data. Human safety data is minimal, with a low risk of allergic reaction. Not FDA-approved; most supply consists of unregulated products sold online.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Note: Endoluten is not a single peptide but a mixture of natural peptides extracted from pineal glands by Khavinson's patented method. All component peptides are under 5 kDa, but the product has no single defined amino acid sequence. It is included here as part of the Khavinson bioregulator system.

Endoluten is a natural peptide bioregulator containing peptide complex A-8, derived from the pineal gland (epiphysis) of young calves. Developed by Professor Vladimir Khavinson, it is one of the flagship products in the Cytomaxes bioregulator line and is considered the cornerstone of Khavinson's anti-aging peptide regimens. The pineal gland is central to melatonin production, circadian rhythm regulation, and neuroendocrine system coordination, making Endoluten one of the most broadly targeted bioregulators in the system.

According to Khavinson's research, Endoluten normalizes metabolism in neuroendocrine system cells and melatonin secretion, regulates hormonal metabolism, and helps prevent atrophic processes in the pineal gland. It is recommended for recovery of neuroendocrine regulation after disease, during pathological menopause, in cancer patients after radiation/chemotherapy, under extreme environmental stress, and during aging to normalize melatonin secretion levels. The pineal peptides are reported to have beneficial effects on immune, cardiovascular, and reproductive systems, as well as carbohydrate metabolism.

Endoluten connects to the broader Khavinson research on Epithalamin (the injectable pineal peptide extract) and Epitalon (the synthetic tetrapeptide Ala-Glu-Asp-Gly), both of which have more extensive published research including effects on telomerase activation, circadian rhythm restoration, and lifespan extension in animal models. Endoluten is the oral capsule form designed for convenient long-term supplementation.

How it works in the body

A bioregulator peptide complex derived from pineal gland tissue. It regulates the expression of genes involved in melatonin synthesis and neuroendocrine signaling. By restoring pineal function, it helps normalize circadian rhythm, sleep-wake cycles, and hormonal cascades that decline with aging.

Research overview

Endoluten is supported by the broader Epithalamin/Epitalon research program, which is the most extensively published of all Khavinson bioregulators. Key findings include: telomerase activation in human somatic cells (Bull Exp Biol Med, 2003), lifespan extension of 20-40% in animal models, melatonin secretion normalization in elderly subjects, circadian rhythm restoration, and mortality reduction in long-term (6-12 year) human follow-up studies. The large-scale Kiev study followed elderly patients treated with Epithalamin + Thymalin for 6-12 years and reported significantly reduced mortality. Endoluten specifically (as the oral capsule form) has fewer standalone publications but benefits from the mechanistic and clinical data generated for the injectable form. Product literature describes studies showing neuroendocrine normalization and melatonin regulation.

Who researches Endoluten?

Commonly researched by

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

  • People researching cardiovascular health

    Studied for effects on heart function, blood pressure, or vascular health.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(3)

Rated by level of concern

  • Allergic reaction to bovine pineal-derived peptides

    Low

    Manufacturer/clinical-study descriptions of Endoluten composition; no published adverse-event literature located

  • Interaction with melatonin supplements

    Low

    Mechanistic inference from PMID 15452611; no interaction study exists

  • Hormonal effects in hormone-sensitive conditions

    Theoretical

    Mechanistic extrapolation from PMID 15664732; no human endocrine-safety data

Interaction summary(7)

Rated by direction with this peptide

  • Melatonin / melatonin receptor agonists (ramelteon, agomelatine, tasimelteon)

    CautionTheoretical

    Additive melatonergic load is plausible if Endoluten raises endogenous nocturnal melatonin, potentially causing excess sedation or unintended circadian phase shifts; no interaction study has been performed, and the human melatonin data are from the injectable analogue Epithalamin, not oral Endoluten.

    Mechanistic; human melatonin-rhythm data PMID 15452611

  • Antihypertensives (ACE inhibitors, ARBs, calcium channel blockers)

    CautionTheoretical

    Epithalamin, the injectable analogue of the same pineal peptide class, reduced the 24-hour arterial pressure profile in middle-aged and elderly women with IHD and hypertension, so additive blood-pressure reduction is conceivable and warrants monitoring rather than avoidance. The BP finding itself is a small single-center Russian trial; the combination has never been studied.

    PMID 18546838

  • Sedative-hypnotics (benzodiazepines, Z-drugs, sedating antihistamines)

    CautionTheoretical

    Any genuine increase in nighttime melatonin could compound next-morning sedation and fall risk in older adults, the exact population Endoluten is marketed to; entirely unstudied.

    Mechanistic inference; no published data

  • Beta-blockers (propranolol, atenolol) and other beta-1 antagonists

    CautionTheoretical

    Efficacy-reducing rather than safety-relevant: beta-adrenergic blockade suppresses the norepinephrine-driven nocturnal AANAT step in pineal melatonin synthesis, so a peptide acting upstream on pineal gene expression would plausibly have its effect blunted rather than potentiated. No study has tested the combination.

    Established pineal physiology; no study of this combination

  • Immunosuppressants and biologic immune modulators

    CautionTheoretical

    Khavinson-group reports attribute immune-restorative effects to pineal/thymic bioregulators, so opposing pharmacology is conceivable in transplant or autoimmune patients. The underlying immune claims rest on unblinded single-center cohort data with no immunological endpoint reported for Endoluten specifically, so this is a low-confidence flag rather than a documented interaction.

    PMID 14523363

  • Glucose-lowering agents (insulin, sulfonylureas)

    CautionTheoretical

    Pineal peptides have been reported to restore age-related pancreatic hormonal function in animal and primate work, and melatonin signaling modulates insulin secretion, so glucose monitoring is reasonable if both are used. No human glycemic endpoint has been measured for Endoluten.

    PMID 15664732 (Khavinson, Exp Gerontol 2005, pineal peptides and pancreatic hormonal function)

  • Hormone-sensitive cancer therapy (tamoxifen, aromatase inhibitors, GnRH agonists)

    CautionTheoretical

    Melatonergic and pineal signaling interacts with estrogen-axis biology in animal carcinogenesis models in both directions, and no human oncology safety data exist for Endoluten, so use alongside endocrine therapy is unstudied territory rather than a known benefit or a known harm.

    Mechanistic; no clinical data

Known risks(3)

  • Allergic reaction to bovine pineal-derived peptides

    Low

    Theoretical risk; no serious adverse events reported in available literature.

  • Interaction with melatonin supplements

    Low

    Concurrent use with exogenous melatonin could theoretically alter circadian rhythm regulation.

  • Hormonal effects in hormone-sensitive conditions

    Moderate

    As a neuroendocrine regulator, theoretical concern exists for individuals with hormone-sensitive cancers or endocrine disorders.

Drug interactions(3)

  • Melatonin supplements

    Potential additive effect on circadian regulation; coordinate timing

  • Hormone replacement therapy

    Theoretical interaction via neuroendocrine pathway modulation

  • Immunosuppressants

    Pineal peptides may influence immune function; monitor if on immunosuppressive therapy

Research & benefits

Evidence base

Evidence Level
Limited Evidence (with stronger data for related injectable form)
Total Studies
10
Human Studies
300

Direct clinical evidence for oral Endoluten capsules is limited to Russian clinical reports. However, the related injectable form Epithalamin and synthetic peptide Epitalon have more extensive published research, including long-term human follow-up studies showing mortality reduction (Kiev study, 6-12 year follow-up), telomerase activation studies, and melatonin normalization data. The oral capsule form is extrapolated from these findings but has not been independently validated.

Researched for(5)

Rated by confidence in the evidence

  • Melatonin secretion normalization during aging

    Speculative

    Nighttime melatonin restoration is shown for injectable Epithalamin, not directly tested for oral Endoluten.

    PMID 15452611 (Korkushko, Bull Exp Biol Med 2004) and PMID 17969590 (Korkushko, Adv Gerontol 2007) — both studied injectable Epithalamin, not Endoluten; no primary source demonstrates this effect for oral Endoluten itself

  • Neuroendocrine system regulation

    Low

    Mostly animal and cell data; human evidence limited to open-label studies with soft endpoints.

    PMID 15664732 (Khavinson, Exp Gerontol 2005); PMID 14523363 (Khavinson & Morozov, Neuro Endocrinol Lett 2003)

  • Circadian rhythm support

    Low

    Inferred from melatonin and blood pressure rhythm data, not measured with sleep studies.

    PMID 15452611 (Korkushko, Bull Exp Biol Med 2004); PMID 18546838 (Merkur'eva & Ryzhak, Adv Gerontol 2008)

  • Potential anti-aging effects via telomerase activation (related Epitalon research)

    Speculative

    Telomerase activation shown in cell cultures for a related peptide, Epitalon, not for Endoluten.

    PMID 12937682 (Khavinson, Bondarev & Butyugov, Bull Exp Biol Med 2003); Al-Dulaimi et al., Biogerontology 2025, doi:10.1007/s10522-025-10315-x

  • Immune and cardiovascular system support (indirect via neuroendocrine regulation)

    Low

    Single-center cohort studies report large benefits, but effect sizes look implausibly high.

    PMID 14523363 (Khavinson & Morozov, Neuro Endocrinol Lett 2003); PMID 18546838 (Merkur'eva & Ryzhak, Adv Gerontol 2008)

Benefits(5)

  • Melatonin secretion normalization during aging

    Khavinson Institute clinical reports; Epithalamin clinical literature

  • Neuroendocrine system regulation

    Endoluten product clinical studies; epiphysis peptide research program

  • Circadian rhythm support

    Epithalamin/Epitalon research; Khavinson Biogerontology 2009 review

  • Potential anti-aging effects via telomerase activation (related Epitalon research)

    Bull Exp Biol Med 2003; Epitalon telomerase studies

  • Immune and cardiovascular system support (indirect via neuroendocrine regulation)

    Khavinson multi-system bioregulator research

Key studies(2)

  1. Anisimov VN, Khavinson VKh

    Biogerontology

    2010

    35-year comprehensive review showing peptide bioregulators (including pineal peptides) restore physiological functions and reduce mortality in aging populations over 6-12 year follow-up periods. Animal models show 20-40% lifespan extension.

  2. Khavinson VKh, Kuznik BI, Ryzhak GA

    Advances in Gerontology

    2013

    Describes peptide bioregulators as a new class of geroprotectors with evidence for life extension and functional restoration in both animals and humans.

Regulation & availability

Why researchers look at it

Endoluten targets the pineal gland -- the master clock of the neuroendocrine system -- with peptides aimed at restoring melatonin secretion and circadian regulation. It is considered the cornerstone of Khavinson's bioregulator anti-aging system.

Estimated cost
$40-80/mo (capsules)
FDA status
Not FDA-approved; not reviewed by FDA; sold as dietary supplement internationally
WADA status
Not specifically named on the 2026 WADA Prohibited List. This does not establish permission: S0 prohibits pharmacological substances without governmental approval for human therapeutic use when no subsequent section applies. Supplement marketing does not establish therapeutic approval. Endoluten's product-specific classification requires confirmation.
Prescribability
Available in Russia as dietary supplement; not approved in USA/EU
Availability
Sold as a dietary supplement; not available through conventional pharmacies in the USA or EU.

International status

  • EU

    Not approved

  • US

    Not approved

  • Russia

    Used clinically (Khavinson bioregulator protocol)

  • Worldwide

    Limited to Russian clinical use

Regulatory timeline(3)

  1. 1980s-1990s
    Epithalamin (injectable) developed for Soviet military; clinical research initiated
  2. 2000s
    Endoluten (oral capsule form) developed and commercialized as Cytomaxes supplement in Russia
  3. 2010s
    sublingual form introduced

Sources & FAQs

Research sources(2)

Frequently asked questions(3)

Why is Endoluten considered the most important bioregulator?

The pineal gland is considered the master regulator of the neuroendocrine system. Khavinson's research suggests that pineal peptides influence melatonin production, circadian rhythms, and downstream hormonal cascades, making it the foundational bioregulator in anti-aging protocols.

What is the relationship between Endoluten, Epithalamin, and Epitalon?

All three target the pineal gland. Epithalamin is the injectable polypeptide extract, Endoluten is the oral capsule form (natural Cytomaxes), and Epitalon is the synthetic tetrapeptide (Ala-Glu-Asp-Gly). They represent different delivery formats of pineal peptide bioregulation.

Does Endoluten actually increase melatonin?

Published melatonin findings in elderly subjects concern Epithalamin. They do not establish that oral Endoluten normalizes melatonin secretion.